Close Menu

NEW YORK – Children's Hospital of Philadelphia (CHOP) and Gustave Roussy in France have received $1.3 million to conduct parallel Phase III trials of Pfizer's ALK inhibitor lorlatinib (Lorbrena) in ALK-mutated, pediatric neuroblastoma patients.

The grant was awarded by a group of research charities, led by Solving Kids' Cancer UK and Solving Kids' Cancer US. The funds will be split between CHOP and Gustave Roussy and spread over four years.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.

Apr
27
Sponsored by
Biognosys

This webinar, the first in our Next-Generation Proteomics for Precision Oncology series, will discuss how proteomics can help overcome the challenges of treating COVID-19 patients with oncologic comorbidities.

Jun
16
Sponsored by
Biognosys

This webinar, the second in our Next-Generation Proteomics for Precision Oncology series, will discuss how unbiased discovery proteomics can be used to identify new key mechanisms and signatures supporting clinical decision-making for melanoma patients.